The closing price of Bluebird bio Inc (NASDAQ: BLUE) was $1.10 for the day, down -5.17% from the previous closing price of $1.16. On the day, 6443977 shares were traded.
Ratios:
Our analysis of BLUE’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.42 and its Current Ratio is at 1.55. In the meantime, Its Debt-to-Equity ratio is 1.36 whereas as Long-Term Debt/Eq ratio is at 1.04.
On December 08, 2023, Morgan Stanley Upgraded its rating to Equal-Weight which previously was Underweight and also upped its target price recommendation from $3 to $7.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 04 ’24 when Obenshain Andrew sold 6,095 shares for $1.53 per share. The transaction valued at 9,311 led to the insider holds 279,998 shares of the business.
Klima Thomas J sold 4,573 shares of BLUE for $6,986 on Mar 04 ’24. The insider now owns 124,840 shares after completing the transaction at $1.53 per share. On Mar 01 ’24, another insider, Colvin Richard A, who serves as the Chief Medical Officer of the company, sold 6,770 shares for $1.53 each. As a result, the insider received 10,342 and left with 118,368 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 9.76 while its Price-to-Book (P/B) ratio in mrq is 0.53.
Stock Price History:
Over the past 52 weeks, BLUE has reached a high of $5.53, while it has fallen to a 52-week low of $0.88.
Shares Statistics:
A total of 192.74M shares are outstanding, with a floating share count of 189.83M. Insiders hold about 1.51% of the company’s shares, while institutions hold 61.93% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by bluebird bio, Inc. analysts. The consensus estimate for the next quarter is $171.54, with high estimates of $15.43 and low estimates of $198.46.
EPS for the following year is $Mutual Fund, with Stocks analysts recommending between $Stocks and $Mutual Fund.
